Ticagrelor (AZD6140) is the first reversibly binding oral P2Y12 receptor antagonist that
blocks ADP‐induced platelet aggregation. Unlike thienopyridines, which irreversibly bind to …

Currently, clopidogrel is recommended for treatment of patients with acute coronary
syndrome and/or percutaneous coronary intervention. However, the delayed onset of the …

Background Cangrelor, a nonthienopyridine adenosine triphosphate analogue, is an
intravenous blocker of the adenosine diphosphate receptor P2Y12. This agent might have a …

Oral antiplatelet drugs are a cornerstone of modern pharmacotherapy in cardiovascular
atherothrombotic diseases. The efficacy of acetylsalicylic acid (ASA, aspirin) and clopidogrel …

Aims To assess the incidence, timing, and relation of drug-eluting stent (DES) thrombosis to
discontinuation of clopidogrel therapy. Methods and results This prospective observational …

Antiplatelet therapy is the mainstay of treatment for patients with cardiovascular disease.
However, some patients experience adverse cardiac events despite treatment with single-or …

This study sought to compare Multiplate impedance platelet aggregometry (IPA) with light
transmission aggregometry (LTA) and the PFA-100 for determining the prevalence of …

Platelet aggregometry has been the reference method employed to detect, diagnose, and
monitor qualitative platelet disorders since the early 1960s. Lumiaggregometry and …

Clopidogrel is a prodrug that has to be converted to an active metabolite by hepatic
cytochrome P450 (CYP) isoenzymes to inhibit platelet aggregation. Individual variability of …

Antiplatelet drugs represent the basis of treatment for car-diovascular atherothrombotic
disease processes. Clopidogrel selectively inhibits the platelet adenosine diphosphate …